ArticleOncoTargets and therapy2019
Ganoderan (GDN) Regulates The Growth, Motility And Apoptosis Of Non-Small Cell Lung Cancer Cells Through ERK Signaling Pathway In Vitro And In Vivo.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- The dual role of Ganoderma lucidum polysaccharides in cancer treatment: Meridian tropism-based direct inhibition and immune-mediated modulation.Journal of the Chinese Medical Association : JCMA · 2026Review
- Unlocking the Potential of Polysaccharides for the Treatment of Lung Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Progress of ERK Pathway-Modulated Natural Products for Anti-Non-Small-Cell Lung Cancer Activity.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A Review of Bioactive Components and Pharmacological Effects ofFood science & nutrition · 2025Review
- MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging and disease · 2024Review
- A review of anti-tumour effects of Ganoderma lucidum in gastrointestinal cancer.Chinese medicine · 2023Review
- Ganoderma lucidum polysaccharide ameliorated diabetes mellitus-induced erectile dysfunction in rats by regulating fibrosis and the NOS/ERK/JNK pathway.Translational andrology and urology · 2022Article
- Management of Combined Therapy (Ceritinib,Life (Basel, Switzerland) · 2022Article
- Mxi1 participates in the progression of lung cancer via the microRNA-300/KLF9/GADD34 Axis.Cell death & disease · 2022Article
- Research Progress on the Anticancer Activities and Mechanisms of Polysaccharides FromFrontiers in pharmacology · 2022Review
- Article
- A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights fromTranslational lung cancer research · 2021Review
- Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value.Journal of fungi (Basel, Switzerland) · 2021Review
- Polysaccharides from sporoderm-removed spores ofOncology letters · 2021Article
- High-Pressure Supercritical COFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most common malignant tumor worldwide. About 90% of lung cancers are considered non-small cell lung cancer (NSCLC). Ganoderan (GDN) is one of the components of
methodsCell growth was measured by Cell Counting kit-8 and colony formation assay, while cell motility was measured by transwell assay and wound healing assay. Apoptosis was measured by flow cytometry analysis and TUNEL staining, and protein expression was detected by Western blotting and immunohistochemistry.
resultsPrevious studies have shown that GDNB has the effects of hyperglycemic and kidney protection. However, the role of GDNB in tumors is currently unknown. This study elaborated the role of GDNB in NSCLC and its underlying molecular mechanisms. The results exerted that GDNB inhibited the growth of H510A and A549 cells by suppressing the expression of ki67 and PCNA. Besides, transwell assay and wound healing assay showed that GDNB inhibited invasion and migration of H510A and A549 cells in a concentration-dependent manner. Moreover, Western blotting also showed that GDNB downregulated the levels of N-cadherin, vimentin and Snail in H510A and A549 cells in a dose-dependent manner, while it upregulated the level of E-cadherin. Additionally, GDNB also promoted apoptosis of H510A and A549 cells by regulating the expression of Bcl-2, Bax, cleaved caspase 3 and cleaved PARP. Animal experiments revealed that GDNB inhibited tumor growth and metastasis, and induced apoptosis of tumor cells in vivo. Mechanically, GDNB suppressed the expression of Ras and c-Myc, and decreased the phosphorylation levels of MEK1/2 and ERK1/2.
conclusionCollectively, all data suggest that GDNB regulates the growth, motility and apoptosis of non-small cell lung cancer cells through ERK signaling pathway in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.